stockrowEdesa Biotech, Inc.
EDSA Healthcare Biotechnology
- EPS
- −140.0%
- Free cash flow
- −81.2%
Quarter to June 2026, against a year earlier
Follow EDSA
Alert me
Edesa Biotech, Inc. (EDSA) EV/Sales
As of 6 November 2026, Edesa Biotech, Inc. (EDSA) trades at a EV/Sales of 28.0×. Over the past ten years it has ranged from −36.8× (December 2018) to 456× (September 2021); the current reading is higher than 37% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2020 | 189× | 318.14% |
| FY2019 | 45.3× | — |
| FY2018 | −29.4× | — |
| FY2017 | 22.4× | 192.21% |
| FY2016 | 7.7× | (86.14%) |
| FY2015 | 55.4× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2020 | 189× | 269.33% |
| Jun 2020 | 51.3× | 175.30% |
| Mar 2020 | 18.6× | (55.18%) |
| Dec 2019 | 41.6× | (8.25%) |
| 18 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MGX Metagenomi Therapeutics, Inc. compare | −4.7× |
| ACET Adicet Bio, Inc. compare | −2.2× |
| IRLA IRulya Therapeutics Inc. compare | n/m |
| ANVS Annovis Bio, Inc. compare | n/m |
| BCTX BRIACELL THERAP compare | n/m |
| PLRZ Polyrizon Ltd. compare | n/m |
| LITS Lite Strategy, Inc. compare | 0.3× |
| ALGS Aligos Therapeutics, Inc. compare | 0.4× |
| EDSA Edesa Biotech, Inc. | 28.0× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)